🎁Top 10 Companies Might Beat Estimates This Week: BDX, TDG, TTD…
[Miser]Hi Tigers,
The following table shows the top 10 companies (ranked by market value) that announced better than expected earnings on November 6, 2023.
Rank | Ticker | Market Cap | EPS | Consensus EPS* Forecast | % Change on Earnings Date | YTD 2023 |
1 | $97.624B | $3.67 | $3.53 | -1.95% | 30.98% | |
2 | $47.9B | $3.31 | $3.26 | 1.64% | 17.57% | |
3 | $38.284B | $2.26 | $1.37 | 6.54% | 39.04% | |
4 | $36.701B | $1.02 | $1 | 0.48% | -20.70% | |
5 | $28.395B | $5.49 | $4.90 | -0.84% | 16.90% | |
6 | $24.545B | $0.73 | ($0.53) | 2.67% | -31.85% | |
7 | $20.726B | $0.47 | $0.44 | 0.04% | 11.72% | |
8 | $18.274B | $0.89 | $0.76 | -1.04% | 31.70% | |
9 | $12.689B | $2.50 | $2.20 | -2.88% | 14.02% | |
10 | $12.076B | $0.35 | $0.31 | -1.38% | 7.29% |
Data source from yahoo.com, as of November 7, 2023.
After the announcement of the results, 5 of the 10 shares have positive returns, the rest have negative returns. How will they continue to perform after earnings?
Feel free to comment with function of bullish & bearish sign.
And you might also be interested in the following stocks, which will release data this week that might beat EPS estimates.
Rank | Symbol | Market Cap | Consensus EPS* Forecast | Last Year's EPS* | Current Price | YTD 2023 |
1 | $74.3B | $3.42 | $2.75 | $256.11 | 0.71% | |
2 | $49.269B | $7.10 | $4.74 | $892.80 | 41.80% | |
3 | $38.088B | $0.13 | $0.03 | $77.70 | 73.72% | |
4 | $34.642B | $1.09 | $0.99 | $50.92 | -20.44% | |
5 | $33.443B | $0.60 | $0.51 | $18.29 | 2.52% | |
6 | $24.023B | $1.33 | $1.20 | $101.80 | 18.19 | |
7 | $23.599B | $0.88 | $0.83 | $122.56 | -10.20% | |
8 | $23.326B | $4.20 | $3.56 | $938.40 | 56.77% | |
9 | $22.754B | $0.05 | $0.02 | $3.91 | 9.52% | |
10 | $21.572B | $0.79 | $0.64 | $40.39 | -13.77% |
Data source from yahoo.com, as of November 7, 2023.
Editor’s note: Feel free to add comments on stocks that interest you. Also read great analysis or trading strategies before any trading actions.
1. Why EPS Matters?
Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.
EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.
Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.
2. Read More >>
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript Summary
NXP Semiconductors (NXPI) Q3 2023 Earnings Call Transcript Summary
Earnings Digest | NXP results signal semiconductor industry rebound!
Diamondback Energy (FANG) Q3 Earnings Call Transcript Summary
BioNTech’s stock rallies after it posts surprise Q3 profit and revenue that tops estimates
🎁Please share with us your winning trades on Q3 earnings season and your most anticipate target in this Earnings season in the comment section.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Definitely$Vertex Pharmaceuticals(VRTX)$ will be my top choice!
Vertex stock is off 52-week highs after a slight miss on revenue. Analysts are also concerned about when the company's pipeline candidates will be accretive to the company's bottom line. For me, I think VRTX stock is a long-term buy candidate, but investors should wait for a better entry point or improved analyst sentiment.
During its earnings call, the company commented on Exa-cel, which presents a potential multibillion-dollar opportunity. Vertex is on track for Exa-cel's launch in the U.S. and Europe, with a focus on engaging authorized treatment centers and payers.
Vertex may be my favorite biotech at the moment, with so much growth left. It's hard to estimate just how much value its pipeline has, but based on the markets it is targeting, I do not see a slowdown in earnings in the next few years, probably more than a decade.
While operating costs have risen due to substantial investments in research and pipeline expansion, Vertex's 2023 guidance remains solid.
The company's promising pipeline, featuring stars like Exa-cel and VX-548, presents significant long-term opportunities in the healthcare sector.
With a forward-looking approach and an eye on growth, Vertex Pharmaceuticals holds immense potential. With such great company under S&P index, it will stimulate the upside of $SPDR S&P 500 ETF Trust(SPY)$ $Direxion Daily S&P 500 Bull 3X(SPXL)$ $S&P Biotech Bull 3X Shares(LABU)$ How do you like the company?
@TigerStars @MillionaireTiger @CaptainTiger @Tiger_comments @TigerClub @Tiger_SG @TigerEvents
I like $NXP Semiconductors NV(NXPI)$ the most among the listed 10 companies as I foresee semiconductor stocks to continue growing due to AI🤖 and EV🔋🚗🚙 NXP delivered quarterly revenue of $3.43 billion, $34 million above the midpoint of guidance and revenue trends in mobile, industrial and IoT, and automotive end markets all performed in line or better than anticipated😃 Thanks loads @Tiger_Earnings ❣️
🌟🌟🌟$Vertex Pharmaceuticals(VRTX)$ has just announced its 3Q 23 results with product revenue of USD 2.48 billion, a 6% increase compared to Q3 22. It also raises its full yer 2023 product revenue guidance to USD 9.85 billion.
Vertex is a global biotechnology company that invests in Scientific Innovation to create transformative medicines for people with serious diseases. Vertex has multiple approved medicines that treat the underlying causes of Cystic Fibrosis which is a rare life threatening genetic disease.
Vertex is also preparing to launch exa-cel in various countries pending the FDA approval.
Performance wise Vertex is up 32% year todate.
Wall Street Analysts are bullish on Vertex with a Buy rating, Target price of USD 398.19, an upside potential of 5.8%.
I like that Vertex Pharmaceuticals is giving hope to people around the world who are suffering from serious diseases and who wish to be cured. Life is precious and Vertex Pharmaceuticals is at the forefront in research and technology including cutting edge gene editing therapy to help these people.
@Tiger_Earnings @TigerStars @TigerClub @Tiger_SG
volatile etf $iShares 20+ Year Treasury Bond ETF(TLT)$, but I still have confidence in the market. tag friends to get coins. @Shyon @GoodLife99 @HelenJanet @rL